Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy Lozeron P; Denier C; Lacroix C; Adams DArch Neurol 2009[Apr]; 66 (4): 490-7OBJECTIVE: To report the long-term follow-up (mean, 41 months; range, 25-55 months) of patients with demyelinating neuropathy occurring after tumor necrosis factor-alpha (TNF-alpha) blocker treatment (infliximab [Remicade], etanercept [Enbrel], and adalimumab [Humira]). BACKGROUND: Demyelinating neuropathy is a rare adverse event of anti-TNF-alpha therapy. Improvement usually occurs after drug interruption and/or in association with usual treatments for demyelinating neuropathies. DESIGN: Case report with review of the previously published cases. SETTING: University hospital in Le Kremlin-Bicetre, France: tertiary reference center for peripheral neuropathies and national reference center for rare peripheral neuropathies (www.nnerf.fr). PATIENTS: Five patients (4 men, mean age, 47 years) who developed a demyelinating neuropathy during anti-TNF-alpha therapy. MAIN OUTCOME MEASURE: Development of neuropathy. RESULTS: Neuropathy developed early (8 months) after treatment introduction. Various clinical patterns were encountered, including pure sensory neuropathy. Immunomodulating treatments were always required for neuropathy control. Chronic demyelinating neuropathy developed either after change of anti-TNF-alpha drug or spontaneously after treatment discontinuation without any drug reintroduction. CONCLUSION: Influence of anti-TNF-alpha treatment continuation on the long-term course of neuropathy is variable, suggesting that anti-TNF-alpha treatment withdrawal is not always necessary for neuropathy control.|Adalimumab[MESH]|Adult[MESH]|Anti-Inflammatory Agents/*adverse effects/therapeutic use[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/*adverse effects/therapeutic use[MESH]|Arthritis, Psoriatic/*drug therapy[MESH]|Arthritis, Rheumatoid/*drug therapy[MESH]|Crohn Disease/*drug therapy[MESH]|Demyelinating Diseases/*chemically induced/diagnosis[MESH]|Drug Therapy, Combination[MESH]|Etanercept[MESH]|Female[MESH]|Follow-Up Studies[MESH]|Hidradenitis Suppurativa/*drug therapy[MESH]|Humans[MESH]|Immunization, Passive[MESH]|Immunoglobulin G/*adverse effects/therapeutic use[MESH]|Immunosuppressive Agents/*adverse effects/therapeutic use[MESH]|Infliximab[MESH]|Lymphotoxin-alpha/*antagonists & inhibitors[MESH]|Male[MESH]|Middle Aged[MESH]|Neurologic Examination/drug effects[MESH]|Plasma Exchange[MESH]|Receptors, Tumor Necrosis Factor/therapeutic use[MESH]|Spondylitis, Ankylosing/*drug therapy[MESH]|Treatment Outcome[MESH] |
